STAT May 25, 2023
Kerry Dooley Young

This article is adapted from the latest STAT Report: Decoding Medicare: 10 key coverage decisions and how they’re made.

Medicare’s decision to withhold coverage for Biogen’s Aduhelm despite the Food and Drug Administration’s approval of the Alzheimer’s drug has revived longstanding questions about how the federal program determines whether it will pay for new drugs and devices.

In its decision, the Centers for Medicare and Medicaid Services cited a lack of sufficient evidence for Aduhelm’s effectiveness, and limited payment for the drug to patients enrolled in research studies. The agency said it would apply the same limits to other new Alzheimer’s drugs that, like Aduhelm, target amyloid plaques in the brain.

The move has drawn strong praise from some. But...

Today's Sponsors

Upfront Healthcare

Today's Sponsor


Topics: Biotechnology, Insurance, Medicare, Pharma, Pharma / Biotech
Lawsuits To Block Medicare Drug Price Negotiations Are Very Unpopular Among Voters
Drugmakers face down deadline on Medicare price negotiations
Federal judge declines to block Medicare drug price negotiations
CMS: A Step Where a Leap is Needed
Amicus Briefs In Merck Lawsuit Defend Constitutionality Of Medicare Drug Price Negotiation Program

Share This Article